Lv6
2140 积分 2024-02-20 加入
Efficacy of tirzepatide, lanifibranor, and resmetirom in metabolic dysfunction-associated steatotic liver disease: a meta-analysis of high-quality randomized controlled trials
5小时前
已完结
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
1个月前
已完结
Non-invasive tests for evaluating treatment response in NAFLD
1个月前
已完结
Development and Validation of a Score for Fibrotic Nonalcoholic Steatohepatitis
1个月前
已完结
Development and validation of a non-invasive score for at-risk metabolic dysfunction-associated steatohepatitis in individuals with obesity undergoing bariatric surgery
1个月前
已完结
Metabolic effects and mechanism of action of the pan-PPAR agonist lanifibranor
2个月前
已完结
Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD
2个月前
已完结
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
2个月前
已完结
Predictors of fibrosis, clinical events and mortality in MASLD: Data from the Global-MASLD study
3个月前
已完结
COURVOISIER'S LAW
4个月前
已完结
皖公网安备34019202002308
